Qiyu Sun1, Xingwang Jia2, Jing Gao2, Pengjun Zhang2, Wenjun Mou2, Caie Yang2, Hongli Tong2, Xinyu Wen2, Yaping Tian3. 1. Department of Clinical Biochemistry, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China; Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Road, Chengde 067000, China. 2. Department of Clinical Biochemistry, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. 3. Department of Clinical Biochemistry, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. Electronic address: 13683048264@163.com.
Abstract
BACKGROUND: MicroRNAs (miRNAs) are involved in cardiac developmental and pathological processes, and serum profile is useful for identifying novel miRNAs. METHODS AND RESULTS: Serum samples were collected from unstable angina pectoris (UAP) and subclinical atherosclerotic (AS) patients. Solexa sequencing was used to predict novel miRNAs in 15 control individuals, 15 AS patients and 15 UAP patients. After bioinformatics analysis and filtering out in the newest version of miRbase (version 20.0), three novel miRNAs were validated in 80 control individuals, 80 AS patients and 80 UAP patients by quantitative reverse transcriptase polymerase chain reaction. Two of the three novel microRNAs (N1 and N3) were expressed at the highest levels in the AS group. N1 had an area under curve (AUC) of 0.811 (95% confidence interval 0.743-0.880) for AS. N3 showed a moderate separation with an area under curve (AUC) of 0.748 (95% confidence interval 0.664-0.833) for AS. Combined the two novel microRNAs can significantly distinguish AS from control. CONCLUSIONS: Three novel miRNAs were identified by Solexa sequencing and two of them may be new potential predictors for arthrosclerosis.
BACKGROUND: MicroRNAs (miRNAs) are involved in cardiac developmental and pathological processes, and serum profile is useful for identifying novel miRNAs. METHODS AND RESULTS: Serum samples were collected from unstable angina pectoris (UAP) and subclinical atherosclerotic (AS) patients. Solexa sequencing was used to predict novel miRNAs in 15 control individuals, 15 AS patients and 15 UAP patients. After bioinformatics analysis and filtering out in the newest version of miRbase (version 20.0), three novel miRNAs were validated in 80 control individuals, 80 AS patients and 80 UAP patients by quantitative reverse transcriptase polymerase chain reaction. Two of the three novel microRNAs (N1 and N3) were expressed at the highest levels in the AS group. N1 had an area under curve (AUC) of 0.811 (95% confidence interval 0.743-0.880) for AS. N3 showed a moderate separation with an area under curve (AUC) of 0.748 (95% confidence interval 0.664-0.833) for AS. Combined the two novel microRNAs can significantly distinguish AS from control. CONCLUSIONS: Three novel miRNAs were identified by Solexa sequencing and two of them may be new potential predictors for arthrosclerosis.